Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Change in Acquisitions & Divestments: 2016-2025

Historic Change in Acquisitions & Divestments for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to $61.5 million.

  • Rhythm Pharmaceuticals' Change in Acquisitions & Divestments rose 35.75% to $61.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $288.4 million, marking a year-over-year increase of 21.98%. This contributed to the annual value of $260.6 million for FY2024, which is 26.57% down from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Change in Acquisitions & Divestments is $61.5 million, which was down 24.06% from $81.0 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Change in Acquisitions & Divestments peaked at $156.7 million during Q3 2021, and registered a low of $45.3 million during Q3 2024.
  • Its 3-year average for Change in Acquisitions & Divestments is $74.2 million, with a median of $70.0 million in 2024.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Change in Acquisitions & Divestments plummeted by 60.76% in 2022, and later soared by 144.12% in 2023.
  • Rhythm Pharmaceuticals' Change in Acquisitions & Divestments (Quarterly) stood at $69.0 million in 2021, then decreased by 13.63% to $59.6 million in 2022, then rose by 6.12% to $63.3 million in 2023, then soared by 38.30% to $87.5 million in 2024, then skyrocketed by 35.75% to $61.5 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $61.5 million for Q3 2025, versus $81.0 million for Q2 2025 and $58.3 million for Q1 2025.